Intermediate and Long-Term Outcomes of Survivors of Acute Kidney Injury Episodes by Sawhney, Simon et al.
Article
Intermediate and Long­Term Outcomes of Survivors of 
Acute Kidney Injury Episodes
Sawhney, Simon, Marks, Angharad, Fluck, Nick, Levin, Adeera, 
Prescott, Gordon and Black, Corri
Available at http://clok.uclan.ac.uk/25120/
Sawhney, Simon, Marks, Angharad, Fluck, Nick, Levin, Adeera, Prescott, Gordon ORCID: 0000­
0002­9156­2361 and Black, Corri (2017) Intermediate and Long­Term Outcomes of Survivors of 
Acute Kidney Injury Episodes. American Journal of Kidney Diseases, 69 (1). pp. 18­28. ISSN 
0272­6386  
It is advisable to refer to the publisher’s version if you intend to cite from the work.
http://dx.doi.org/10.1053/j.ajkd.2016.05.018
For more information about UCLan’s research in this area go to 
http://www.uclan.ac.uk/researchgroups/ and search for <name of research Group>.
For information about Research generally at UCLan please go to 
http://www.uclan.ac.uk/research/ 
All outputs in CLoK are protected by Intellectual Property Rights law, including
Copyright law.  Copyright, IPR and Moral Rights for the works on this site are retained 
by the individual authors and/or other copyright owners. Terms and conditions for use 
of this material are defined in the http://clok.uclan.ac.uk/policies/
CLoK
Central Lancashire online Knowledge
www.clok.uclan.ac.uk
Original InvestigationFrom the
Collaborati
Scotland; 3
4University
Received
2016. Origi
Address c
Applied Hea
hill, Aberdee
18Intermediate and Long-term Outcomes of Survivors of Acute
Kidney Injury Episodes: A Large Population-Based Cohort Study
Simon Sawhney, MBChB,1,2,3 Angharad Marks, MBChB,1,2,3 Nick Fluck, MBChB,2
Adeera Levin, MD, FRCPC,4 Gordon Prescott, PhD,1 and Corri Black, MBChB1,2,3
Background: The long-term prognosis after acute kidney injury (AKI) is variable. It is unclear how the
prognosis of AKI and its relationship to prognostic factors (baseline kidney function, AKI severity, prior AKI
episodes, and recovery of kidney function) change as follow-up progresses.
Study Design: Observational cohort study.
Setting & Participants: The Grampian Laboratory Outcomes Morbidity and Mortality Study II (GLOMMS-II)
is a large regional population cohort with complete serial biochemistry and outcome data capture through data
linkage. From GLOMMS-II, we followed up 17,630 patients hospitalized in 2003 through to 2013.
Predictors: AKI identified using KDIGO (Kidney Disease: Improving Global Outcomes) serum creatinine
criteria, characterized by baseline kidney function (estimated glomerular filtration rate [eGFR]$ 60, 45-59, 30-44,
and,30 mL/min/1.73 m2),AKIseverity (KDIGOstage), 90-day recoveryof kidney function,andpriorAKIepisodes.
Outcomes: Intermediate- (30-364 days) and long-term (1-10 years) mortality and long-term renal
replacement therapy.
Measurements: Poisson regression in time discrete intervals. Multivariable Cox regression for those at risk
in the intermediate and long term, adjusted for age, sex, baseline comorbid conditions, and acute admission
circumstances.
Results:Of 17,630 patients followed up for amedian of 9.0 years, 9,251 died. Estimated incidences of hospital
AKI were 8.4% and 17.6% for baseline eGFRs$ 60 and ,60 mL/min/1.73 m2, respectively. Intermediate-term
(30-364 days) adjusted mortality HRs for AKI versus no AKI were 2.48 (95% CI, 2.15-2.88), 2.50 (95% CI,
2.04-3.06), 1.90 (95% CI, 1.51-2.39), and 1.63 (95% CI, 1.20-2.22) for eGFRs$ 60, 45 to 59, 30 to 44,
and ,30 mL/min/1.73 m2, respectively. Among 1-year survivors, long-term HRs were attenuated: 1.44 (95%
CI, 1.31-1.58), 1.25 (95% CI, 1.09-1.43), 1.21 (95% CI, 1.03-1.42), and 1.08 (95% CI, 0.85-1.36), respectively.
The excess long-term hazards in AKI were lower for lower baseline eGFRs (P for interaction 5 0.01).
Limitations: Nonprotocolized observational data. No adjustment for albuminuria.
Conclusions: The prognostic importance of a discrete AKI episode lessens over time. Baseline kidney
function is of greater long-term importance.
Am J Kidney Dis. 69(1):18-28.ª 2016 The Authors. Published by Elsevier Inc. on behalf of the National Kidney
Foundation, Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/
by/4.0/).
INDEX WORDS: Acute kidney injury (AKI); chronic kidney disease (CKD); baseline kidney function; survival;
mortality; epidemiology; outcomes; prognosis; AKI recovery; acute on chronic kidney disease.Editorial, p. 3cute kidney injury (AKI) occurs in 1 in 7 hos-A pital admissions.1 Even those with small in-
creases in creatinine levels have 4-fold greater
hospital mortality than those with no creatinine level
increase.2 Overall, for those who survive to hospital
discharge, the prognosis remains poor. However,
although 2 previous systematic reviews reported long-
term increased mortality and long-term renal1University of Aberdeen Applied Renal Research
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n, AB25 2ZD. E-mail: simon.sawhney@abdn.ac.ukreplacement therapy (RRT) after AKI (vs no AKI),
there was substantial heterogeneity in both outcomes
(I2 . 85%).3,4 To discuss risk and plan care for in-
dividual patients requires a better understanding of
what drives variation, which patients are at elevated
risk, and how long risk remains elevated.5
Clinical guidelines recognize that the long-term
prognostic factors for AKI are poorly understood.6,7
The KDIGO (Kidney Disease: Improving Global
Outcomes) guideline advocates follow-up of all pa-
tients with AKI,6 and UK guidelines recommend 2016 The Authors. Published by Elsevier Inc. on behalf of the
National Kidney Foundation, Inc. This is an open access article
under the CC BY license (http://creativecommons.org/licenses/by/
4.0/).
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Box 1. AKI Criteria for This Study and Definitions for AKI
Severity, Prior AKI, and 7-Day Recovery
AKI criteria definitionsa
 Modified criterion 1: Scr$ 1.5 times higher than median
of all Scr values 8-90 d ago, or 91-365 d ago if no tests
between 8-90 d
 Criterion 2: Scr $ 1.5 times higher than lowest Scr
within 7 d
 Criterion 3: Scr . 26 mmol/L higher than lowest Scr
within 48 h
AKI severity staging definitionsb
 Stage 1: Increase in Scr of 0.3 mg/dL; or index/baseline
ratio $1.5-,2
 Stage 2: Index/baseline ratio $2-,3
 Stage 3: Index/baseline ratio $3; or $1.5 and index
Scr. 4 mg/dL (or 33 upper reference interval if
age ,18 y)
Prior AKI episodes definition
 No prior AKI: First AKI episode in 2003 not preceded by
any previous AKI episodes in prior 91-1,095 d
 Prior AKI: First AKI episode in 2003 preceded by at least
1 previous AKI episode in prior 91-1,095 d
7-day AKI recovery status definitionc
 Complete recovery: Last Scr within 7 d of AKI, 1.2 times
higher than baseline Scr at diagnosis
 Partial recovery: Last Scr within 7 d of AKI .1.2-,1.5
times higher than baseline Scr at diagnosis
 Nonrecovery: Last Scr within 7 d of AKI$ 1.5 times
higher than baseline Scr at diagnosis, or still receiving
urgent RRT
 “Untested”: No repeat blood tests taken within 7 d of AKI
diagnosis
Note: Conversion factor for Scr in mg/dL to mmol/L, 388.4.
Abbreviations: AKI, acute kidney injury; RRT, renal replace-
ment therapy; Scr, serum creatinine.
aOne of 1-3; note criterion 1 modified from National Health
Service England AKI warning criteria to enable recognition of
distinct, prior, and subsequent AKI episodes.
bBased on peak Scr within 90 days of diagnosis.
cFor 90-day recovery status, we applied the same thresholds
but using the last available Scr within 90 days of AKI onset.
Long-term Prognosis of AKIsurveillance for at least 2 to 3 years.8 Monitoring of all
patients may be prudent, but in clinical practice, some
patients are prioritized over others, only a minority see
a nephrologist, and follow-upmay be brief.9,10Without
more detailed prognostic studies, it is difﬁcult for cli-
nicians to communicate individual risks and prioritize
high-risk patients for an appropriate duration.
Potential drivers of variation in AKI prognosis
include the limited availability of pre-AKI (baseline)
data in previous AKI deﬁnitions, differences in the
severity of AKI, level of baseline kidney function, de-
gree of subsequent recovery of kidney function, and
variation in the prognostic role of AKI as follow-up
time progresses.3,4,11-13 These factors are potentially
quantiﬁable in all patients with AKI, but have not been
systematically explored in any one study. In particular,
the changing prognostic role of AKI at different levels
of baseline function and at different follow-up times has
received little attention, and the relevance of prior AKI
episodes has not previously been studied.11 Further-
more, the time at which recovery of kidney function is
assessed has varied in previous studies, and it is unclear
how often this will have reclassiﬁed patients.
The Grampian Laboratory Outcomes Morbidity
and Mortality Study II (GLOMMS-II) is a population
cohort linking national and regional data sources in a
single UK health authority. Uniquely, all biochem-
istry data are obtained by a single laboratory service
regardless of clinical location (inpatient, outpatient,
and community), thus minimizing the loss of baseline
and follow-up data. We have previously exploited
GLOMMS-II to study different approaches to using
kidney function data to deﬁne AKI in clinical practice
and prognostic research.14,15
To guide decisions and discussions with patients
about the implications of an AKI episode, we have used
GLOMMS-II to study how the prognosis after isolated
AKI episodes changes during the course of a long
follow-up from intermediate (30-364 days) to long term
(1-10 years). We hypothesized that the adverse prog-
nosis of AKI would lessen over time and the role of
AKI prognostic factors (baseline, severity, and prior
AKI episodes) would change as follow-up progressed.
METHODS
Population
The GLOMMS-II was developed through novel data linkage
of regional biochemistry results (1999-2009) to hospital episode
data, the local renal information management system, and the
Scottish Renal Registry for long-term RRT, morbidity, and
outcomes.14,16 It includes all patients with abnormal kidney
function test results (estimated glomerular ﬁltration rate
[eGFR] , 60 mL/min/1.73 m2) and a 20% sample of those with
normal kidney function. It has been extensively used in renal
research, including AKI.14,16-18 All serum creatinine measure-
ments are isotope-dilution mass spectrometry2aligned and pro-
cessed by a single biochemistry service. Data linkage enablesAm J Kidney Dis. 2017;69(1):18-28population follow-up without formal patient recruitment, which
minimizes selection biases. Information Services Division (ISD)
Scotland refreshed the linkages using the community health in-
dex, a unique identiﬁer for all residents in Scotland, to connect
each AKI episode to individual hospital admissions. There were
no patients without a community health index indexed in the ISD
population “spine,” meaning that all records were linkable. The
ISD reports precision of 99.9% for record linkages.19 We ob-
tained approval from the Privacy Advisory Committee (study
number XRB14137) and the Regional Ethics Committee (refer-
ence 14/NW/1371), which waived the requirement for informed
consent for this study. Data were hosted and managed by
Grampian Data Safe Haven.20
Exposure: Admission With AKI in 2003
The exposure was the ﬁrst hospital admission with AKI in 2003.
We excluded those with AKI who were not admitted to the hos-
pital within 7 days. This was to ensure that both the exposed and
comparator groups contained only admitted patients and because19
Table 1. Patient Characteristics by Baseline Kidney Function and AKI Severity, and by Prior AKI
Of 17,630 Patients in the Entire Cohort by Baseline eGFR and AKI Severity
Of 3,426 AKI Patients Only
Normal Baseline Kidney Function:
eGFR $ 60 mL/min/1.73 m2
Baseline Decreased Kidney Function:
eGFR , 60 mL/min/1.73 m2
No AKI
(n 5 8,269)
AKI 1
(n 5 1,263)
AKI 2
(n 5 541)
AKI 3
(n 5 354) P
No AKI
(n 5 5,935)
AKI 1
(n 5 809)
AKI 2
(n 5 271)
AKI 3
(n 5 188) P
No Prior AKI
(n 5 2,738)
Prior AKI
(n 5 688) P
Characteristics
Age, y 60 [45-72] 73 [63-80] 72 [60-80] 69 [58-79] ,0.001 78 [71-84] 81 [74-87] 81 [74-87] 79 [70-84] ,0.001 76 [66-83] 77 [66-84] 0.09
Age $ 70 y 2,440 (29.5) 764 (60.5) 308 (56.9) 173 (48.9) ,0.001 4,659 (78.5) 699 (86.4) 239 (88.2) 148 (78.7) ,0.001 1,847 (67.5) 484 (70.3) 0.01
Female sex 4,609 (55.7) 621 (49.2) 276 (51.0) 160 (45.2) 3,578 (60.3) 463 (57.2) 165 (60.9) 91 (48.4) 1,414 (51.6) 362 (52.6)
Male sex 3,660 (44.3) 642 (50.8) 265 (49.0) 194 (54.8) ,0.001 2,357 (39.7) 346 (42.8) 106 (39.1) 97 (51.6) 0.005 1,324 (48.4) 326 (47.4) 0.1
Ward
Medical 2,990 (36.2) 439 (34.8) 211 (39.0) 121 (34.2) 2,069 (34.9) 273 (33.7) 93 (34.3) 80 (42.6) 916 (33.5) 301 (43.8)
Care of the elderly 330 (4.0) 163 (12.9) 71 (13.1) 46 (13.0) 640 (10.8) 172 (21.3) 58 (21.4) 32 (17.0) 438 (16.0) 104 (15.1)
Surgical 3,062 (37.0) 259 (20.5) 78 (14.4) 50 (14.1) 1,828 (30.8) 123 (15.2) 32 (11.8) 25 (13.3) 475 (17.4) 92 (13.4)
Critical care unit 514 (6.2) 311 (24.6) 154 (28.5) 127 (35.9) 370 (6.2) 162 (20.0) 71 (26.2) 45 (23.9) 730 (26.7) 140 (20.4)
Other 1,373 (16.6) 91 (7.2) 27 (5.0) 10 (2.8) ,0.001 1,028 (17.3) 79 (9.8) 17 (6.3) 6 (3.2) ,0.001 179 (6.5) 51 (7.4) 0.2
Charlson comorbid conditionsa
MI 255 (3.1) 91 (7.2) 36 (6.7) 23 (6.5) ,0.001 418 (7.0) 123 (15.2) 30 (11.1) 29 (15.4) ,0.001 201 (7.3) 131 (19.0) 0.2
CHF 155 (1.9) 100 (7.9) 36 (6.7) 27 (7.6) ,0.001 499 (8.4) 157 (19.4) 61 (22.5) 47 (25.0) ,0.001 227 (8.3) 201 (29.2) 0.4
PVD 167 (2.0) 83 (6.6) 26 (4.8) 18 (5.1) ,0.001 285 (4.8) 97 (12.0) 25 (9.2) 14 (7.4) ,0.001 175 (6.4) 89 (12.9) 0.9
CBVC 206 (2.5) 87 (6.9) 43 (7.9) 15 (4.2) ,0.001 439 (7.4) 94 (11.6) 25 (9.2) 13 (6.9) ,0.001 180 (6.6) 97 (14.1) 0.007
Dementia 65 (0.8) 30 (2.4) 11 (2.0) 12 (3.4) ,0.001 142 (2.4) 37 (4.6) 9 (3.3) 8 (4.3) 0.001 61 (2.2) 46 (6.7) 0.8
CPD 383 (4.6) 157 (12.4) 73 (13.5) 36 (10.2) ,0.001 407 (6.9) 92 (11.4) 42 (15.5) 18 (9.6) ,0.001 284 (10.4) 134 (19.5) 0.5
Rheumatic disease 140 (1.7) 34 (2.7) 22 (4.1) 14 (4.0) ,0.001 139 (2.3) 39 (4.8) 18 (6.6) 7 (3.7) ,0.001 79 (2.9) 55 (8.0) 0.1
Peptic ulcer disease 123 (1.5) 52 (4.1) 19 (3.5) 14 (4.0) ,0.001 160 (2.7) 27 (3.3) 16 (5.9) 5 (2.7) 0.02 83 (3.0) 50 (7.3) 0.7
Mild liver disease 88 (1.1) 35 (2.8) 17 (3.1) 15 (4.2) ,0.001 55 (0.9) ,5a (-) 6 (2.2) ,5a (-) 0.02 46 (1.7) 34 (4.9) 0.7
Severe liver disease 32 (0.4) 11 (0.9) 10 (1.8) 5 (1.4) ,0.001 13 (0.2) ,5a (-) ,5a (-) ,5a (-) 0.3 16 (0.6) 16 (2.3) 0.07
DM without complications 301 (3.6) 125 (9.9) 58 (10.7) 43 (12.1) ,0.001 470 (7.9) 129 (15.9) 44 (16.2) 40 (21.3) ,0.001 267 (9.8) 172 (25.0) 0.7
DM with complications 15 (0.2) 19 (1.5) 9 (1.7) 7 (2.0) ,0.001 62 (1.0) 33 (4.1) 13 (4.8) 7 (3.7) ,0.001 48 (1.8) 40 (5.8) 0.9
Hemiplegia 39 (0.5) 13 (1.0) 7 (1.3) ,5a (-) 0.007 34 (0.6) 9 (1.1) ,5a (-) ,5a (-) 0.1 18 (0.7) 20 (2.9) 0.4
Malignancy 520 (6.3) 213 (16.9) 104 (19.2) 72 (20.3) ,0.001 530 (8.9) 83 (10.3) 38 (14.0) 31 (16.5) ,0.001 420 (15.3) 121 (17.6) 0.9
Metastatic malignancy 111 (1.3) 58 (4.6) 41 (7.6) 28 (7.9) ,0.001 80 (1.3) 16 (2.0) 6 (2.2) 7 (3.7) 0.03 128 (4.7) 28 (4.1) 0.9
Note: The cohort includes all with abnormal kidney function and a 20% random sample of those with normal kidney function. Patients with no AKI and normal baseline function are therefore
under-represented in this table. Values for categorical variables are given as number (percentage); values for continuous variables, as median [interquartile range]. P values are from c2 test, or
Kruskal-Wallis test when appropriate.
Abbreviations and definitions: AKI, acute kidney injury (1-3 denote severity stage); CBVD, cerebrovascular disease; CHF, congestive heart failure; CPD, chronic pulmonary disease; DM,
diabetes mellitus; eGFR, estimated glomerular filtration rate; MI, myocardial infarction; PVD, peripheral vascular disease.
aResults for human immunodeficiency virus and small numbers not reported to prevent patient identification.
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Figure 1. Flow chart of study population from GLOMMS-II (Grampian Laboratory Morbidity and Mortality Study II). Abbreviations:
AKI, acute kidney injury; eGFR, estimated glomerular filtration rate.
Long-term Prognosis of AKIKDIGO-based AKI criteria perform differently in patients who are
not admitted to the hospital.21 We deﬁned AKI using a modiﬁ-
cation of the National Health Service (NHS) England AKI
“e-alert” algorithm, derived from the KDIGO AKI deﬁnition
(Box 1).22 The ﬁrst result meeting AKI criteria was recorded as the
start of an AKI episode, and the corresponding “look-back” result
from the criteria was used as the baseline.
We have demonstrated the performance of the NHS England
algorithm elsewhere,14 but because it does not organize blood tests
into discrete AKI episodes, we developed a modiﬁed version that
was capable of distinguishing AKI episode severity and prior and
subsequent AKI episodes. The original algorithm uses an 8- to 365-
day look-back to estimate the median baseline creatinine level, but
a prior AKI episode could result in a falsely high estimate of
baseline from tests in the past year leading to underdetection of
recurrent AKI.23 Therefore, as illustrated in Fig S1 (available as
online supplementary material), we modiﬁed the algorithm criteria
to a 1.5-fold or greater increase from median creatinine level within
8 to 90 days in those with an available test, and further look-back to
365 days only in those without a more recent test (criterion 1, Box
1). To ensure clinical relevance for those using the original NHS
England algorithm, we compared diagnostic agreement and 30-day
mortality in a sensitivity analysis.
Deﬁnitions for AKI Severity, Prior AKI Episodes, and
Recovery of Kidney Function
Deﬁnitions are summarized inBox1.WedeterminedAKI severity
stages 1 to 3 using the peak creatinine level in the AKI episode
relative to the baseline creatinine level. We counted the number of
prior AKI episodes that occurred in the preceding 91 to 1,095 days
(ie, 3 years). Given the varying deﬁnitions of recovery and theAm J Kidney Dis. 2017;69(1):18-28KDIGO recommendation of reassessment at 90 days,6,13,24-26 we
determined how an earlier assessment (7 days) compared to a later
assessment (90days)with regard to recovery status and completeness
of repeat testing. Because our interest was in the classiﬁcation of
those with complete return to baseline,27 those receiving RRT were
classed as nonrecovery rather than grouped separately.
Comparator: Admission Without AKI in 2003
Comparators were patients admitted to the hospital in 2003,
who had a blood test for kidney function during admission, and
did not have AKI. To ensure that they had the opportunity to
develop AKI in 2003, the last admission in 2003 was used. We
used their hospital admission creatinine as baseline.
Outcomes
Outcomes were mortality and long-term RRT (dialysis or
transplantation).
Follow-up
Follow-up was from the date of initial hospital admission to
2013. Follow-up was through data linkage to the national register
rather than direct patient contact. Migration from Grampian to
beyond Scotland was negligible for the period and age-mix of the
cohort.28 Those not registered as dead during follow-up were
therefore assumed to be still alive.
Covariates of Interest
We used International Classiﬁcation of Diseases, Tenth Revision
codes for Charlson comorbid conditions from the 5 years prior to
admission as previously described and validated.29,30 We also
determined diagnostic categories (eg, circulatory system and21
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Sawhney et alrespiratory system) related to the acute admission by using the
admission categories grouped and recorded in International
Classiﬁcation of Diseases, Tenth Revision, as previously utilized
elsewhere2. We used the CKD-EPI (Chronic Kidney Disease
Epidemiology Collaboration) creatinine equation to describe
baseline kidney function in 4 eGFR groups31: normal, $60; mild
decrease, 45 to 59; moderate decrease, 30 to 44; and severe
decrease, ,30 mL/min/1.73 m2. We did not include measures of
proteinuria because only a minority of the population had been
tested.We also recorded whether the admission was an emergency
readmission and the specialty involved during the hospital
admission with the following priority when more than 1 was
involved: critical care, surgical, care of the elderly, medical, and
“other” (eg, obstetrics and psychiatry).
Analysis
We reported the incidence of hospital AKI in those with and
without baseline decreased kidney function. Due to cohort
sampling, those with normal baseline function and no AKI were
under-represented. This means that the incidence of AKI among
those admitted with normal baseline function cannot be taken
directly from the data presented in Table 1 because this would
overestimate its occurrence. Therefore, the incidence of AKI was
calculated directly for those with baseline decreased kidney
function and estimated by multiplying out the sampled fraction
for those with normal baseline function. We described overall
characteristics and outcomes stratiﬁed by baseline kidney func-
tion, AKI severity stage, and history of prior AKI episodes. We
compared patient recovery of kidney function status at 7 and 90
days, including the proportion of patients who improved, dete-
riorated, and died. We reported crude mortality and long-term
RRT and plotted 10-year mortality by AKI stage using 1 2
Kaplan-Meier curves. We assessed mortality in intervals of 0 to
30 days, 31 to 90 days, 91 to 182 days, 183 to 364 days, 1 to less
than 3 years, and 3 to 5 years. Within each interval, we computed
mortality rates by AKI stage stratiﬁed by baseline eGFR group.
Using Poisson regression, we calculated age- and sex-adjusted
mortality rate ratios (RRs) within each period by AKI stage
and prior AKI episodes. We then determined long-term (1-10
years) mortality among those alive at 1 year using multivariable
Cox regression adjusted for age, sex, and covariates of interest.
Based on previous literature, we included an interaction term
between baseline eGFR and AKI on mortality.11,32 In a series of
sensitivity analyses, we also calculated hazard ratios (HRs) for
intermediate outcomes (30-364 days), and when analysis was
restricted to those younger than 75 years, to patients with AKI
without complete recovery to baseline, and those who also had
prior AKI episodes. All analyses were conducted using Stata/SE
13.0 (StataCorp LP).
RESULTS
Cohort Description
The GLOMMS-II is outlined in Fig 1. Of 17,630
hospitalized patients, 3,426 (19.6%) had AKI. The
estimated incidence of AKI in the hospital was
17.6% among patients with baseline decreased kid-
ney function and 8.4% among patients with normal
baseline function. The 10-year observation period
extended from 2003 until 2013 and comprised
114,696 person-years (median follow-up, 9.0 years).
Characteristics of Patients With and Without AKI
Patient characteristics for those with and without
AKI are described in Table 1. Data are stratiﬁed by22 Am J Kidney Dis. 2017;69(1):18-28
Figure 2. Cumulative mortality by acute kidney injury (AKI) stage (1-3 denote severity stage), stratified by baseline kidney function.
Abbreviation: eGFR, estimated glomerular filtration rate (mL/min/1.73 m2).
Long-term Prognosis of AKIbaseline kidney function to allow for population
sampling. The left panel describes patients with and
without AKI further stratiﬁed by AKI severity. Of
those with normal baseline function, patients with
AKI were older, received more critical care, and had
more comorbid conditions than patients without AKI,
but age and comorbid conditions varied little with
AKI severity. The pattern was similar for those with
baseline decreased kidney function, though all groups
were older and had more comorbid conditions.
Additional data for patient characteristics in eGFR
subgroups are provided in Table S1.
The Table 1 right panel focuses on the 3,426 pa-
tients with AKI, by history of prior AKI episodes.
There were 688 (20.1%) patients who had prior AKI
episodes, of which 38.4% had occurred within the last
1 year. Patients with prior AKI episodes had more
comorbid conditions than those without prior AKI
(eg, congestive heart failure and diabetes).
As reported in Fig S2, the recovery status of many
patients with AKI changed between 7 and 90 days. Of
the 3,081 of 3,426 patients with AKI still alive at 7
days, by 90 days, 20.4% had improved, 9.9% had
deteriorated, 20.5% had died, and 49.1% were un-
changed from 7 days. At 7 days, a substantial pro-
portion (360 of 3,081 [11.7%]) had also not yet had a
repeat blood test. For these reasons, subsequent
analysis used recovery of kidney function at 90 days.
Mortality and RRT Outcomes
Tables 2 and S2 summarize crude mortality and
long-term RRT. Irrespective of baseline function,
mortality was higher for AKI versus no AKI, even atAm J Kidney Dis. 2017;69(1):18-2810 years (Table 2). In those with normal baseline
kidney function, long-term RRT was rare, irrespective
of AKI episode, severity, or duration (Table S2). In
those with baseline decreased kidney function, long-
term RRT was most frequent in patients with AKI
stage 3. It was also more frequent in those with prior
AKI episodes. Further data for long-term RRT in
eGFR subgroups are available in Table S3.
Effect of AKI on Mortality Over Intermediate- and
Long-term Intervals
Regardless of baseline eGFR, the more severe the
AKI, the greater the initial mortality (Fig 2). How-
ever, after 1 year, the mortality curves no longer
diverged. Figure 3 describes the change in mortality
rates over the ﬁrst 5 years in greater detail. Figure 3A
to D describes mortality rates in patients at risk in
each of 6 intervals (0-30 days, 31-90 days, 91-182
days, 183-364 days, 1-,3 years, and 3-5 years) by
AKI severity and stratiﬁed by baseline eGFR.
Figure 3E describes mortality rates by prior AKI ep-
isodes. Age- and sex-adjusted RRs and 95% conﬁ-
dence intervals (CIs) are reported. At all levels of
baseline eGFR, early mortality rates were higher in
those with AKI than without AKI and highest in
those with AKI stages 2 to 3. The early (0-30 days)
mortality RRs for AKI (vs no AKI) were greater in
those with higher baseline eGFRs: RRs of 6.80 (95%
CI, 5.24-8.82), 4.22 (95% CI, 3.00-5.96), 2.63 (95%
CI, 1.82-3.79), and 1.93 (95% CI, 1.20-3.10) for AKI
stage 1 at eGFRs $ 60, 45 to 59, 30 to 44,
and ,30 mL/min/1.73 m2, respectively. In the same
eGFR subgroups, the association of AKI (vs no AKI)23
0-30 days 31-90 days 91-182 days 183-364 days 1-3 years 3-5 years 
0-30 days 31-90 days 91-182 days 183-364 days 1-3 years 3-5 years 
0-30 days 31-90 days 91-182 days 183-364 days 1-3 years 3-5 years 
n=10427 
Figure 3. Mortality rates and age- and sex-adjusted rate ratios by (A-D) baseline estimated glomerular filtration rate (eGFR) group
and (E) prior acute kidney injury (AKI; 1-3 denote severity stage). Abbreviation: ref, reference group.
24 Am J Kidney Dis. 2017;69(1):18-28
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0-30 days 31-90 days 91-182 days 183-364 days 1-3 years 3-5 years 
0-30 days 31-90 days 91-182 days 183-364 days 1-3 years 3-5 years 
Mortality rates by prior AKI 
n=3426 
E  
Figure 3 (Cont’d).
Long-term Prognosis of AKIwith mortality also diminished over time: RRs at 1
year of 1.84 (95% CI, 1.55-2.17), 1.89 (95% CI, 1.49-
2.39), 1.47 (95% CI, 1.12-1.93), and 1.01 (95% CI,
0.67-1.53), respectively. Those with prior AKI epi-
sodes (vs no prior episodes) had similar early mor-
tality, but greater mortality from 6 months onward.
Adjusted Long-term Mortality
Table 3 describes the relationship between AKI
and long-term mortality (conditional on surviving 1
year) in adjusted models (age, sex, baseline comorbid
conditions, and acute circumstances). There was
effect modiﬁcation by baseline eGFR (P for
interaction 5 0.01). Among 1-year survivors, the
adjustedmortality HRs for AKI (vs noAKI) were lower
at lower baseline eGFRs: HRs of 1.44 (95% CI, 1.31-
1.58), 1.25 (95% CI, 1.09-1.43), 1.21 (95% CI, 1.03-Am J Kidney Dis. 2017;69(1):18-281.42), and 1.08 (95%CI, 0.85-1.36) for eGFRs$ 60, 45
to 59, 30 to 44, and,30 mL/min/1.73 m2, respectively.
As demonstrated by a comparison to those who had no
AKI and baseline eGFRs$ 60 mL/min/1.73 m2
(Table 3), AKI made little difference among those with
lower baseline eGFRs because their mortality was high
irrespective of AKI.
Sensitivity Analyses
In a series of sensitivity analyses for mortality
outcomes (Table S4), adjusted mortality HRs were
higher when calculated for intermediate outcomes
(30-364 days): 2.48 (95% CI, 2.15-2.88), 2.50 (95%
CI, 2.04-3.06), 1.90 (95% CI, 1.51-2.39), and 1.63
(95% CI, 1.20-2.22) for eGFRs $ 60, 45 to 59, 30 to
44, and ,30 mL/min/1.73 m2, respectively. HRs
were similar when limited to those younger than 7525
Table 3. Ten-Year Mortality Conditional on Surviving the First Year
No. Age- & Sex-Adjusted HR (95% CI) Fully adjusted HRa (95% CI)
eGFR $ 60, no AKI 7,741 1.00 (reference) 1.00 (reference)
eGFR $ 60, AKI 1,325 1.74 (1.60-1.89) 1.44 (1.31-1.58)
AKI vs no AKI for eGFR $ 60 group 1.74 (1.60-1.89) 1.44 (1.31-1.58)
eGFR 45-59, no AKI 3,243 1.11 (1.04-1.19) 1.09 (1.02-1.17)
eGFR 45-59, AKI 350 1.77 (1.56-2.02) 1.36 (1.19-1.56)
AKI vs no AKI for eGFR 45-59 group 1.59 (1.40-1.81) 1.25 (1.09-1.43)
eGFR 30-44, no AKI 1,337 1.48 (1.36-1.61) 1.40 (1.29-1.52)
eGFR 30-44, AKI 219 2.16 (1.85-2.52) 1.69 (1.66-2.11)
AKI vs no AKI for eGFR 30-44 group 1.49 (1.25-1.70) 1.21 (1.03-1.42)
eGFR , 30, no AKI 425 2.08 (1.85-2.34) 1.87 (1.66-2.11)
eGFR , 30, AKI 121 2.28 (1.85-2.81) 2.02 (1.62-2.50)
AKI vs no AKI for eGFR , 30 group 1.10 (0.87-1.38) 1.08 (0.85-1.36)
Note: Multivariable Cox regression with interaction terms between AKI and baseline eGFR. Adjusted HRs are reported with
reference to no AKI and normal baseline kidney function and for baseline eGFR groups calculated using the interaction terms.
eGFRs expressed in mL/min/1.73 m2. Boldface indicates AKI vs no AKI within each eGFR group calculated using the interaction
terms.
Abbreviations: AKI, acute kidney injury; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio.
aAdjusted for age, sex, Charlson comorbid conditions, hospital admission circumstances, International Classification of Diseases,
Tenth Revision categories for acute hospital admission diagnoses, and with interaction terms between AKI and baseline eGFR.
Sawhney et alyears or when limited to patients with AKI without
complete recovery to baseline at 90 days. Although
those with prior AKI episodes had higher mortality
HRs, this could be explained by adjusting for co-
morbid conditions and acute circumstances.
In this study, we modiﬁed the widely used NHS
England AKI warning algorithm to enable the
grouping of blood tests into discrete AKI episodes
and the identiﬁcation of prior AKI episodes. There
was substantial overlap with the original algorithm
with 99.2% agreement in diagnosis and a k statistic of
0.95. Moreover, 30-day AKI mortality differed by
only 0.2% (20.1% modiﬁed algorithm, 19.9% original
algorithm).
DISCUSSION
The relationship between a discrete episode of AKI
and outcome is complex. This large population study
with long follow-up demonstrates the diminishing
prognostic role of AKI over time, with risk only
modestly increased among 1-year survivors, espe-
cially those with baseline decreased kidney function.
Both intermediate- and long-term mortality with AKI
were modiﬁed by baseline kidney function, with the
greatest association of AKI with mortality in those
with normal baseline function. In contrast, although
AKI was not associated with signiﬁcantly increased
long-term mortality among those with baseline
eGFRs , 30 mL/min/1.73 m2, this group of patients
still had the highest absolute mortality risk. Over time,
there were also different prognostic roles for AKI
severity and prior AKI. Severe AKI had greater short-
term mortality, but AKI severity was less relevant
as follow-up progressed. Patients with prior AKI26episodes had greater long-term mortality, although
this could be explained by comorbid conditions and
acute circumstances. Finally, although patients with
AKI received more long-term RRT, RRT was a rare
outcome in the absence of baseline decreased kidney
function.
This analysis is consistent with and extends
previous work. Previous studies have also noted
effect modiﬁcation by baseline function12,32,33 and
a diminishing role of AKI after hospital discharge.34,35
This analysis now shows that the diminishing role of
AKI continues for up to 1 year after AKI and is
present at all levels of baseline kidney function. The
description of prior AKI as a prognostic factor is also
novel and important. One in 5 patients with AKI had
prior AKI episodes, with worse long-term mortality.
Prior AKI was particularly common in those with heart
failure, which is consistent with a recent study that
reported increased recurrent AKI in heart failure but
did not describe the long-term consequences.36
Finally, the 2-fold increased incidence of hospital
AKI in those with baseline decreased kidney function
(vs normal baseline function) is in agreement with
recent reports elsewhere.37
A strength of this analysis is our use of a large
unselected population all served by a single
biochemistry service, and laboratory data capture all
patients throughout the time course of observation,
pre– and post–hospital admission. The unique situa-
tion ensures the completeness of the data over a
prolonged follow-up and overcomes the shortcomings
of other studies wherein selective laboratory testing or
access to tests would lead to missing baseline or
follow-up data. We also based our AKI deﬁnition onAm J Kidney Dis. 2017;69(1):18-28
Long-term Prognosis of AKIan existing e-alert algorithm. Our analysis is therefore
particularly relevant for clinicians who are evaluating
patients with AKI e-alerts or are developing similar
AKI e-alert systems. However, we recognize and
have reported elsewhere that some misclassiﬁcation
of CKD occurs.15
A relative limitation, which may be also a
strength for real-world generalizability, is the fact that
laboratory data were not protocolized with respect to
intervals of data collection. Blood testing performed at
clinical discretion rather than in standardized testing
intervals introduces an ascertainment bias. This is not
unique to our study and reﬂects real-life practice, but it
is possible that we have missed some AKI cases. In
addition, long-term RRTwas a rare outcome. Although
this prevented more detailed subgroup analyses, the
paucity of long-term RRT among people without
baseline decreased kidney function was still striking.
A key message of this study is that risk after AKI is
not static, but changes over the course of a long
follow-up. The diminishing association of an AKI
episode with mortality is accompanied by greater
importance of long-term factors (baseline kidney
function and history of prior AKI episodes) over acute
factors (AKI severity). Future work should now
explore whether these factors at different time points
can be used to form prognostic prediction tools for
use in clinical practice.
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